A Phase 4 interventional study of Etanercept , Methotrexate and Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide in Rheumatoid Arthritis, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 27 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2010-08-30.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing etanercept in Arthritis, Rheumatoid — 4 open to participants now, 5 under way, 1 of them phase 3. Etanercept · Arthritis, Rheumatoid.
Among the 69 studies testing etanercept in Arthritis, Rheumatoid, this one is the 17th largest by enrollment, is one of 5 that started in 2007, is one of 39 in phase 4, and was the 18th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 69 studies testing etanercept in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Etanercept: first FDA approval 1998 (ENBREL), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 144 across the 69 interventional studies. Of the 53 that completed or were terminated, 31 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 69 have an industry lead sponsor. The 10 most frequent:
This study is registered under Wyeth is now a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
152 studies in Arthritis, Rheumatoid by Pfizer: 2 open now, 2 under way, none of them phase 3. Of 149 finished, 105 (70%) have results posted.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 29th largest by enrollment of the 86 interventional ones that give a count, is one of 13 that started in 2007, is one of 17 in phase 4, and was the 21st registered.
Pfizer’s Arthritis, Rheumatoid studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 69 studies testing etanercept in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 152 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy of etanercept with usual disease-modifying anti-rheumatic drug (DMARD) therapy in the treatment of moderate to severe rheumatoid arthritis (RA) over 16 weeks in the Asia Pacific region.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Etanercept + Methotrexate
Drug: Etanercept , Methotrexate
DMARD therapy Methotrexate + Sulfasalazine/Hydroxychloroquine/Leflunomide
Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide
Drug pages: Etanercept · Methotrexate
* Etanercept: 25 mg twice weekly over 16 weeks, SC * Methotrexate: \> 7.5 mg/week and no more than 25 mg/week, PO
Drug pages: Methotrexate · Sulfasalazine · Hydroxychloroquine · Leflunomide
* Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO * Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO * Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day * Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily
Change From Baseline in Adjusted Mean of American College of Rheumatology Response (ACR-N) Area Under Curve (AUC) Over 16 Weeks
ACR-N = the lowest of 3 values (percent change in the number of swollen joints, percent change in the number of tender joints, and median of the other 5 measures in the ACR core data set). Negative numbers indicate worsening. The ACR-N AUC was calculated using the trapezoidal rule as the ACR-N multiplied by the duration of the assessment period (in weeks) and was presented as %-weeks.
Time frame: 16 weeks
Percentage of Participants Achieving ACR 20, 50, and 70 Responses
Response includes improvement in tender or swollen joints as well as 20 percent improvement in three of the other five criteria. Required: ≥ 20%, 50% or 70% improvement in tender joint count ≥ 20% , 50% or 70% improvement in swollen joint count and at least 20%, 50%, 70% improvement in 3 of the following 5:Patient pain assessment , Patient global assessment ,Physician global assessment, Patient self-assessed disability.
Time frame: Week 16
Percentage of Participants Achieving DAS28 <3.2 (Low Disease Activity) and <2.6 (Remission)
Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR)) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).
Time frame: Week 16
Percent Change From Baseline in DAS28 at Week 16
Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR)) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).
Time frame: Week 16
Percentage of Participants Achieving European League Against Rheumatism (EULAR) Moderate or Good Response
EULAR Response Criteria DAS28) improvement at week 16. Good response was defined as \>1.2 improvement in DAS from Baseline and DAS attained during follow-up of ≤2.4. Non-responders were participants with improvement of ≤0.6 or participants with improvement of \>0.6 but ≤1.2 and DAS attained during follow-up of \>3.7. Remaining participants were classified as moderate. Scores of good and moderate were considered to have therapeutic response.
Time frame: Week 16
Percentage of Participants With DAS28 Improvement of ≥0.6 and ≥1.2
Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).
Time frame: Week 16
Percent Change From Baseline in Painful and Swollen Joint Counts
Participant's assessment of pain - A horizontal pain visual analog scale (VAS) (0-100 mm) is used to assess the participants current level of pain; 0 = no pain and 100 = worst pain. Swollen joint count - ACR swollen joint count, an assessment of 28 joints. Joints are classified as either swollen or not swollen.
Time frame: Week 2, 4, 8, 12, 16
Percent Change From Baseline in Physician And Subject Global Assessments
The Physician Global Assessment of Disease Activity: The participant's disease activity is estimated over the last two - three days by the physician; A zero (0) means no disease activity and a ten (10) means extreme disease activity. The Subject Global Assessment of Disease Activity: The participant assesses overall arthritis activity. A zero (0) means no disease activity and a ten (10) means extreme disease activity.
Time frame: Week 2, 4, 8, 12, 16
Percent Change From Baseline in Duration (Minutes) of Morning Stiffness
The duration of morning stiffness on the day of examination should be determined by asking the following two questions: When did you awaken this morning? When were you able to resume your normal activities without stiffness? Duration of morning stiffness is equal to the time elapsed between the above two times in minutes; If none is present enter 0, If morning stiffness is still continuing, please indicate average of duration of stiffness over the past 3 days. If stiffness persists the entire day 1440 minutes (24h x 60 minutes) should be recorded.
Time frame: Week 2, 4, 8, 12, 16
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
VAS, participant indicates by marking a vertical line at an appropriate position through a horizontal line. The length of the line measures from left (in mm) and the value (in mm) is recorded. General Health VAS, "in general how would you rate your heath over the last 2-3 weeks", 0mm equals very well and 100mm equals extremely bad. Pain VAS: "indicate the amount of pain experienced during the last 2-3 days", 0 mm equals no pain and 100 mm equals pain as bad as it can be. Fatigue VAS: "how fatigued or tired have you been over the last week", range =No Fatigue - Extremely Fatigued.
Time frame: Week 2, 4, 8, 12, 16
Subjects were recruited in the Asia-Pacific Region from June 2007 to October 2008.
| Milestone | ETN/MTX | DMARD/MTX |
|---|---|---|
| Started | 197 | 103 |
| Completed | 193 | 88 |
| Not completed | 4 | 15 |
| Withdrew: Adverse event | 3 | 8 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Withdrawal by subject | 0 | 4 |
ACR-N = the lowest of 3 values (percent change in the number of swollen joints, percent change in the number of tender joints, and median of the other 5 measures in the ACR core data set). Negative numbers indicate worsening. The ACR-N AUC was calculated using the trapezoidal rule as the ACR-N multiplied by the duration of the assessment period (in weeks) and was presented as %-weeks.
| Units on a scale | ETN/MTX | DMARD/MTX |
|---|---|---|
| Change From Baseline in Adjusted Mean of American College of Rheumatology Response (ACR-N) Area Under Curve (AUC) Over 16 Weeks | 434.83 ± 29.18 | 289.54 ± 36.11 |
Response includes improvement in tender or swollen joints as well as 20 percent improvement in three of the other five criteria. Required: ≥ 20%, 50% or 70% improvement in tender joint count ≥ 20% , 50% or 70% improvement in swollen joint count and at least 20%, 50%, 70% improvement in 3 of the following 5:Patient pain assessment , Patient global assessment ,Physician global assessment, Patient self-assessed disability.
| Percentage of Participants | ETN/MTX | DMARD/MTX |
|---|---|---|
| ACR 20 | 78.87 | 58.16 |
| ACR 50 | 56.70 | 34.69 |
| ACR 70 | 19.07 | 7.14 |
Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR)) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).
| Percentage of Participants | ETN/MTX | DMARD/MTX |
|---|---|---|
| Low Disease (DAS28 <3.2) | 39.09 | 18.45 |
| Remission (DAS28 <2.6) | 15.74 | 7.77 |
Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR)) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).
| Percent change | ETN/MTX | DMARD/MTX |
|---|---|---|
| Percent Change From Baseline in DAS28 at Week 16 | 38.32 | 27.46 |
EULAR Response Criteria DAS28) improvement at week 16. Good response was defined as \>1.2 improvement in DAS from Baseline and DAS attained during follow-up of ≤2.4. Non-responders were participants with improvement of ≤0.6 or participants with improvement of \>0.6 but ≤1.2 and DAS attained during follow-up of \>3.7. Remaining participants were classified as moderate. Scores of good and moderate were considered to have therapeutic response.
| Percentage of Participants | ETN/MTX | DMARD/MTX |
|---|---|---|
| Percentage of Participants Achieving European League Against Rheumatism (EULAR) Moderate or Good Response | 87.82 | 73.79 |
Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).
| Percentage of Participants | ETN/MTX | DMARD/MTX |
|---|---|---|
| ≥0.6 | 91.37 | 78.64 |
| ≥1.2 | 82.74 | 66.02 |
Participant's assessment of pain - A horizontal pain visual analog scale (VAS) (0-100 mm) is used to assess the participants current level of pain; 0 = no pain and 100 = worst pain. Swollen joint count - ACR swollen joint count, an assessment of 28 joints. Joints are classified as either swollen or not swollen.
| Percent change | ETN/MTX | DMARD/MTX |
|---|---|---|
| Painful Joints - Week 2 | 34.17 | 27.68 |
| Painful Joints - Week 4 | 46.11 | 36.71 |
| Painful Joints - Week 8 | 55.48 | 49.71 |
| Painful Joints - Week 12 | 65.65 | 55.55 |
| Painful Joints - Week 16 | 68.99 | 57.31 |
| Swollen Joints - Week 2 | 38.59 | 21.32 |
| Swollen Joints - Week 4 | 49.33 | 27.72 |
| Swollen Joints - Week 8 | 59.91 | 44.19 |
| Swollen Joints - Week 12 | 67.97 | 50.48 |
| Swollen Joints - Week 16 | 73.83 | 56.32 |
The Physician Global Assessment of Disease Activity: The participant's disease activity is estimated over the last two - three days by the physician; A zero (0) means no disease activity and a ten (10) means extreme disease activity. The Subject Global Assessment of Disease Activity: The participant assesses overall arthritis activity. A zero (0) means no disease activity and a ten (10) means extreme disease activity.
| Percent change | ETN/MTX | DMARD/MTX |
|---|---|---|
| Physician Global Assessment - Week 2 | 30.40 | 11.83 |
| Physician Global Assessment - Week 4 | 39.58 | 22.81 |
| Physician Global Assessment - Week 8 | 45.86 | 35.41 |
| Physician Global Assessment - Week 12 | 55.00 | 38.67 |
| Physician Global Assessment - Week 16 | 62.05 | 45.04 |
| Subject Global Assessment - Week 2 | 21.84 | 7.24 |
| Subject Global Assessment - Week 4 | 28.94 | 19.22 |
| Subject Global Assessment - Week 8 | 34.92 | 26.08 |
| Subject Global Assessment - Week 12 | 43.18 | 30.10 |
| Subject Global Assessment - Week 16 | 50.76 | 30.55 |
The duration of morning stiffness on the day of examination should be determined by asking the following two questions: When did you awaken this morning? When were you able to resume your normal activities without stiffness? Duration of morning stiffness is equal to the time elapsed between the above two times in minutes; If none is present enter 0, If morning stiffness is still continuing, please indicate average of duration of stiffness over the past 3 days. If stiffness persists the entire day 1440 minutes (24h x 60 minutes) should be recorded.
| Percent change | ETN/MTX | DMARD/MTX |
|---|---|---|
| Week 2 | 54.92 | 16.43 |
| Week 4 | 63.85 | 33.22 |
| Week 8 | 73.41 | 37.35 |
| Week 12 | 79.76 | 52.76 |
| Week 16 | 80.55 | 46.77 |
VAS, participant indicates by marking a vertical line at an appropriate position through a horizontal line. The length of the line measures from left (in mm) and the value (in mm) is recorded. General Health VAS, "in general how would you rate your heath over the last 2-3 weeks", 0mm equals very well and 100mm equals extremely bad. Pain VAS: "indicate the amount of pain experienced during the last 2-3 days", 0 mm equals no pain and 100 mm equals pain as bad as it can be. Fatigue VAS: "how fatigued or tired have you been over the last week", range =No Fatigue - Extremely Fatigued.
| Percent change | ETN/MTX | DMARD/MTX |
|---|---|---|
| General Health - Week 2 | 21.14 | 8.88 |
| General Health - Week 4 | 30.61 | 22.78 |
| General Health - Week 8 | 38.57 | 27.86 |
| General Health - Week 12 | 42.10 | 30.26 |
| General Health - Week 16 | 50.49 | 33.89 |
| Pain - Week 2 | 27.59 | 9.99 |
| Pain - Week 4 | 34.73 | 22.98 |
| Pain - Week 8 | 42.97 | 29.14 |
| Pain - Week 12 | 48.46 | 33.97 |
| Pain - Week 16 | 54.42 | 36.45 |
| Fatigue - Week 2 | 20.90 | 6.63 |
| Fatigue - Week 4 | 30.87 | 19.00 |
| Fatigue - Week 8 | 35.92 | 21.82 |
| Fatigue - Week 12 | 39.65 | 28.65 |
| Fatigue - Week 16 | 46.92 | 30.04 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ETN/MTX | — | 6/197 (3%) | 66/197 (33.5%) |
| DMARD/MTX | — | 3/103 (2.9%) | 71/103 (68.9%) |
| Event | ETN/MTX | DMARD/MTX |
|---|---|---|
| Pneumonia bacterialInfections and infestations | 0/197 | 1/103 |
| Alanine aminotransferase increasedInvestigations | 0/197 | 1/103 |
| Aspartate aminotransferase increasedInvestigations | 0/197 | 1/103 |
| Transaminases increasedInvestigations | 0/197 | 1/103 |
| Myocardial infarctionCardiac disorders | 1/197 | 0/103 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/197 | 0/103 |
| Non-cardiac chest painGeneral disorders | 1/197 | 0/103 |
| CellulitisInfections and infestations | 1/197 | 0/103 |
| Herpes zosterInfections and infestations | 1/197 | 0/103 |
| Pneumocystis jiroveci pneumoniaInfections and infestations | 1/197 | 0/103 |
| Event | ETN/MTX | DMARD/MTX |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 27/197 | 16/103 |
| Alanine aminotransferase increasedInvestigations | 11/197 | 15/103 |
| Aspartate aminotransferase increasedInvestigations | 7/197 | 11/103 |
| LeukopeniaBlood and lymphatic system disorders | 4/197 | 8/103 |
| NauseaGastrointestinal disorders | 4/197 | 8/103 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/197 | 7/103 |
| PyrexiaGeneral disorders | 6/197 | 6/103 |
| Age Continuous(years) | ETN/MTX | DMARD/MTX | Total |
|---|---|---|---|
| Mean | 48.38 ± 11.98 | 48.52 ± 11.25 | 48.43 ± 11.72 |
| Sex: Female, Male(Participants) | ETN/MTX | DMARD/MTX | Total |
|---|---|---|---|
| Female | 180 | 91 | 271 |
| Male | 17 | 12 | 29 |
The record gives a start of Jun 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Etanercept · Methotrexate · Sulfasalazine · Hydroxychloroquine · Leflunomide
Wyeth is now a wholly owned subsidiary of Pfizer →